Skip to main content

ag10

·Code: AG10

ag10: sourced relationships with 2 companies.

ag10 evidence translation

What we can confirm

No verified FDA or trial count is available.

What it means

More than one company relationship is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.

What to watch

Evidence is limited; missing information remains unknown.
BioSniper AIPage evidence connected

Prepared research question

What is verified about ag10, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Related indications

transthyretin amyloidosis (ATTR)ATTR polyneuropathy (ATTR-PN)

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (2)
CompanyDated record stage
ALEXION PHARMACEUTICALS, INC. (ALXN)
licensee · Reported 2020-02-04 · Current development: unknownSource
transthyretin amyloidosis (ATTR)
Preclinical
Eidos Therapeutics, Inc. (EIDX)
developer · Reported 2019-04-15 · Current development: unknownSource
ATTR polyneuropathy (ATTR-PN)
Preclinical

Dated source updates

BridgeBio identifies acoramidis as the project previously called AG10 and reports an Alexion license to develop, manufacture and commercialize it and its chemical forms in Japan. Current development status outside this dated, regional statement is unknown.

Eidos/Alexion Japan license reported by BridgeBio; acoramidis project formerly AG10 · Source date unknown · SEC source